Article
Effects of Recombinant Human Interleukin-6 Alone and in Combination with Recombinant Interleukin-lot and Tumor Necrosis Factor Alpha on Antibacterial Resistance in Mice
Antimicrobial Agents and Chemotherapy
(1992)
Abstract
In this study, recombinant human interleukin-6 (rIL-6) was tested for its ability to alter the resistance of mice
to experimental Listeria monocytogenes infection. Single bolus or repeated injections of rIL-6 by itself did not
increase antilisteria resistance. When rIL-6 was injected in combination with suboptimal concentrations of
rIL-la and tumor necrosis factor alpha (rTNF-a), it did not augment their abilities to mediate protection in
the spleen and had a marginal effect on the level of protection in the liver. Injection of rIL-6 together with
protective doses of rIL-la did not diminish the protection stimulated by the latter. Unlike rIL-la and
recombinant tumor necrosis factor alpha, rIL-6 appears to have little ability to elevate antibacterial resistance.
Disciplines
Publication Date
1992
DOI
10.1128/AAC.36.1.68
Publisher Statement
This is an article from Antimicrobial Agents and Chemotherapy 36 (1992): 68, doi:10.1128/AAC.36.1.68
Posted with permission. Copyright 1992 American Society for Microbiology
Citation Information
Charles J. Czuprynski, Mary Haak-Frendscho, Nancy Maroushek and James F. Brown. "Effects of Recombinant Human Interleukin-6 Alone and in Combination with Recombinant Interleukin-lot and Tumor Necrosis Factor Alpha on Antibacterial Resistance in Mice" Antimicrobial Agents and Chemotherapy Vol. 36 Iss. 1 (1992) p. 68 - 70 Available at: http://works.bepress.com/nancy-boury/4/